自体免疫细胞治疗联合化疗治疗大肠癌的临床研究  

Clinical Study of Autoimmune Cells Therapy combined with Chemotherapy for Colorectal Cancer

作　　者：朱卫[1,2] 李佳丽[2] 张利红[2] 牛静秀[2] 尹晓东[2] 杨雪晶[2,3] 李敬[2] 庞雁[2] 顾林[1] 

机构地区：[1]天津医科大学肿瘤医院,国家肿瘤临床医学研究中心,天津300060 [2]天津市人民医院,天津300121 [3]上海柯莱逊生物技术有限公司,上海201201

出　　处：《中国中西医结合外科杂志》2016年第2期116-119,共4页Chinese Journal of Surgery of Integrated Traditional and Western Medicine

基　　金：浦东新区科技发展基金(PKF2015-C12)

摘　　要：目的:探讨结直肠恶性肿瘤术后化疗与树突状细胞(dendritic cells,DCs)细胞因子诱导的杀伤细胞(cytokine-induced killer,CIK)联合治疗临床应用价值。方法:选择结直肠癌术后化疗联合DC-CIK治疗的病人242例作为联合治疗组,将同期术后只进行化疗的病人463例作为单纯化疗组,分析联合治疗组的免疫功能激活状况以及生存质量,比较两组病人生存率差异。结果:在细胞治疗结束后一周对联合治疗组患者进行迟发性变态反应皮肤试验,结果显示57.85%患者免疫反应被激活,单纯治疗组在治疗过程中体力、食欲、睡眠和体重的变化情况,至少有2项生存质量指标改善的患者有185例(76.45%)。联合治疗组和单纯化疗组病人进行为期18个月的生存率对比,联合治疗组生存率为95.04%,单纯化疗组生存率为89.63%,差异显著(P=0.016)。结论:结直肠癌术后化疗联合DC-CIK治疗可以激活患者的免疫功能,改善患者的生活质量,提高生存率。Objective：kine-induced killer（DC-CIK）in the treatment of colorectal cancer.MethodsTwo hundred and forty-two cas-es of postoperative patients of colorectal cancer treated with chemotherapy combined with DC-CIK in TianjinPeople＇s Hospital were selected as combined treatment group,and 463 cases of colorectal cancer treated withchemotherapy were selected as control group.The type hypersensitivity delayed（DTH）skin test was performedat the end of cell therapy.The changes of physical activity,appetite and sleep were recorded.ResultsIn57.85% of the patients in combined treatment group,DTH was activated.In the same group,there are 185 cases（76.45%）with at least 2 indexes of quality of life being improved.The combined treatment group and controlgroup were compared in 18 months of survival.The survival rate of combined treatment group was 95.04%,andthat of the control group was 89.63%.The differencewas significant（P =0.016）.ConclusionCombinedDC-CIK cell therapy and chemotherapy can activatethe immune function of patients,improve the qualityof life,and improve the survival rate.

关 键 词：早期结直肠癌 树突状细胞疫苗 细胞因子诱导的杀伤细胞 疗效评价 

分 类 号：R735.34[医药卫生—肿瘤]